Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine

Endocrinology

Volumn 143, Issue 12, 2002, Pages 4907-4915

  Twigg, Stephen M ^a   Cao, Zemin ^b   McLennan, Sue V ^c   Burns, Wendy C ^b   Brammar, Gail ^b   Forbes, Josephine M ^b   Cooper, Mark E ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; BOVINE SERUM ALBUMIN; CONNECTIVE TISSUE GROWTH FACTOR; FIBRONECTIN; MESSENGER RNA;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; EXPERIMENTAL MODEL; EXTRACELLULAR MATRIX; KIDNEY DISEASE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES; TREATMENT OUTCOME;

ANIMALS; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; FIBRONECTINS; GENE EXPRESSION; GLOMERULAR MESANGIUM; GLYCOSYLATION END PRODUCTS, ADVANCED; GUANIDINES; HUMANS; IMMEDIATE-EARLY PROTEINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY; LYSINE; MALE; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SERUM ALBUMIN, BOVINE;

EID: 0036892894     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2002-220619     Document Type: Article

References (54)

1. Friedman A 1999 Advanced glycation end-products in diabetic nephropathy. Nephrol Dial Transplant 14:1-9
2. Singh R, Barden A, Mori T, Beilin L 2001 Advanced glycation end-products: A review. Diabetologia 44:129-146
3. Flyvbjerg A 2000 Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease. Diabetologia 43:1205-1223
4. Tsuchida K, Makita Z, Yamagishi S, Atsumi T, Miyoshi H, Obara S, Ishida M, Ishikawa S, Yasumura K, Koike T 1999 Suppression of transforming growth factor β and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia 42:579-588
5. Kelly DJ, Gilbert RE, Cox AJ, Soulis T, Jerums G, Cooper ME 2001 Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy. J Am Soc Nephrol 12:2098-2107
6. Gupta S, Clarkson M, Duggan J, Brady H 2000 Connective tissue growth factor: Potential role in glomerulosclerosis and tubulointerstitial fibrosis. Kidney Int 58:1389-1399
7. Cooper ME 2001 Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 44:1957-1972
8. Frazier K, Williams S, Kothapalli D, Klapper H, Grotendorst GR 1996 Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor. J Invest Dermatol 107:404-411
9. Blom I, van Dijk A, Wieten L, Duran K, Ito Y, Kleij L, Denichilo M, Rabelink T, Weening J, Aten J, Goldschmeding R 2001 In vitro evidence for differential involvement of CTGF, TGFβ, and PDGF-BB in mesangial response to injury. Nephrol Dial Transplant 16:1139-1148
10. Riser BL, Denichilo M, Cortes P, Baker C, Grondin JM, Yee J, Narins RG 2000 Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 11:25-38
11. Murphy M, Godson C, Cannon S, Kato S, Mackenzie HS, Martin F, Brady HR 1999 Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. J Biol Chem 274:5830-5834
12. Adler SG, Kang SW, Feld S, Cha DR, Barba L, Striker L, Striker G, Riser BL, LaPage T, Nast CC 2001 Glomerular mRNAs in human type 1 diabetes: Biochemical evidence for microalbuminuria as a manifestation of diabetic nephropathy. Kidney Int 60:2330-2336
13. Ito Y, Aten J, Bende RJ, Oemar BS, Rabelink TJ, Weening JJ, Goldschmeding R 1998 Expression of connective tissue growth factor in human renal fibrosis. Kidney Int 53:853-861
14. Twigg S, Chen M, Joly A, Chakrapani S, Tsubaki J, Kim H, Oh Y, Rosenfeld R 2001 Advanced glycosylation end products up-regulate connective tissue growth factor (insulin-like growth factor-binding protein-related protein 2) in human fibroblasts: A potential mechanism for expansion of extracellular matrix in diabetes mellitus. Endocrinology 142:1760-1769
15. Twigg S, Joly A, Chen M, Tsubaki J, Kim H, Hwa V, Oh Y, Rosenfeld R 2002 Connective tissue growth factor/IGFBP-rP2 is a mediator in the induction of fibronectin by advanced glycosylation end-products in human dermal fibroblasts. Endocrinology 143:1260-1269
16. Koya D, Haneda M, Nakagawa H, Isshiki K, Sato H, Maeda S, Sugimoto T, Yasuda H, Kashiwagi A, Ways DK, King GL, Kikkawa R 2000 Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC β inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 14:439-447
17. Morrisey K, Steadman R, Williams JD, Phillips AO 1999 Renal proximal tubular cell fibronectin accumulation in response to glucose is polyol pathway dependent. Kidney Int 55:160-167
18. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G 1991 Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 40:1328-1334
19. Soulis T, Cooper ME, Vranes D, Bucala R, Jerums G 1996 Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. Kidney Int 50:627-634
20. Yamauchi A, Takei I, Makita Z, Nakamoto S, Ohashi N, Kiguchi H, Ishii T, Koike T, Saruta T 1997 Effects of aminoguanidine on serum advanced glycation endproducts, urinary albumin excretion, mesangial expansion, and glomerular basement membrane thickening in Otsuka Long-Evans Tokushima fatty rats. Diabetes Res Clin Pract 34:127-133
21. Schmidt F 1961 Enzymatic determination of glucose and fructose simultaneously. Klin Woch 39:1244-1247
22. Allen TJ, Cooper ME, O'Brien RC, Bach LA, Jackson B, Jerums G 1990 Glomerular filtration rate in streptozocin-induced diabetic rats. Role of exchangeable sodium, vasoactive hormones, and insulin therapy. Diabetes 39:1182-1190
23. Bunag R 1973 Validation in awake rats of a tail-cuff method for measuring systolic pressure. J Appl Physiol 34:279-282
24. Rumble JR, Cooper ME, Soulis T, Cox A, Wu L, Youssef S, Jasik M, Jerums G, Gilbert RE 1997 Vascular hypertrophy in experimental diabetes Role of advanced glycation end products. J Clin Invest 99:1016-1027
25. Lopez-Bermejo A, Buckway C, Devi G, Hwa V, Plymate S, Oh Y, Rosenfeld R 2000 Characterization of insulin-like growth factor-binding protein-related proteins (IGFBP-rPs) 1, 2, and 3 in human prostate epithelial cells: Potential roles for IGFBP-rP1 and 2 in senescence of the prostatic epithelium. Endocrinology 141:4072-4080
26. Bonnet F, Cooper ME, Kawachi H, Allen TJ, Boner G, Cao Z 2001 Irbesartan normalises the deficiency In glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia 44:874-877
27. Yang DH, Kim HS, Wilson EM, Rosenfeld RG, Oh Y 1998 Identification of glycosylated 38-kDa connective tissue growth factor (IGFBP-related protein 2) and proteolytic fragments In human biological fluids, and up-regulation of IGFBP-rP2 expression by TGF-β In Hs578T human breast cancer cells. J Clin Endocrinol Metab 83:2593-2596
28. Kim HS, Nagalla SR, Oh Y, Wilson E, Roberts Jr CT, Rosenfeld RG 1997 Identification of a family of low-affinity insulin-like growth factor binding proteins (IGFBPs): Characterization of connective tissue growth factor as a member of the IGFBP superfamily. Proc Natl Acad Sci USA 94:12981-12986
29. Soulis T, Thallas V, Youssef S, Gilbert RE, McWilliam B, Murray-McIntosh RP, Cooper ME 1997 Advanced glycation end products and the receptor for advanced glycated end products co-localise in organs susceptible to diabetic microvascular injury: Immunohistochemical studies. Diabetologia 40:619-628
30. Soulis T, Cooper ME, Sastra S, Thallas V, Panagiotopoulos S, Bjerrum OJ, Jerums G 1997 Relative contributions of advanced glycation and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotechon in diabetic rats. Diabetologia 40:1141-1151
31. Sell DR, Lapolla A, Odetti P, Fogarty J, Monnier VM 1992 Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM. Diabetes 41:1286-1292
32. McLennan SV, Fisher EJ, Yue DK, Turtle JR 1994 High glucose concentration causes a decrease in mesangium degradation. A factor in the pathogenesis of diabetic nephropathy. Diabetes 43:1041-1045
33. Kislinger T, Fu C, Huber B, Qu W, Taguchi A, Du Yan S, Hofmann M, Yan SF, Pischetsrieder M, Stern D, Schmidt AM 1999 N(δ)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 274:31740-31749
34. Oldfield MD, Bach LA, Forbes JM, Nikolic-Paterson D, McRobert A, Thallas V, Atkins RC, Osicka T, Jerums G, Cooper ME 2001 Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest 108:1853-1863
35. Pfaffl MW 2001 A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:E45-E45
36. Steffes MW, Osterby R, Chavers B, Mauer SM 1989 Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes 38:1077-1081
37. Park S, Kim J, Seomun Y, Choi J, Kim D, Han I, Lee E, Chung S, Joo C 2001 Hydrogen peroxide is a novel inducer of connective tissue growth factor. Biochem Biophys Res Commun 284:966-971
38. Suzuma K, Naruse K, Suzuma I, Takahara N, Ueki K, Aiello LP, King GL 2000 Vascular endothelial growth factor induces expression of connective tissue growth factor via KDR, Flt1, and phosphatidylinositol 3-kinase-akt-dependent pathways in retinal vascular cells. J Biol Chem 275:40725-40731
39. Finckenberg P, Lassila M, Inkinen K, Pere AK, Krogerus L, Lindgren L, Mervaala E, Vapaatalo H, Nurminen ML, Ahonen J 2001 Cyclosporine induces myocardial connective tissue growth factor in spontaneously hypertensive rats on high-sodium diet. Transplantation 71:951-958
40. Goppelt-Struebe M, Hahn A, Iwanciw D, Rehm MBB 2001 Regulation of connective tissue growth factor (ccn2; ctgf) gene expression in human mesangial cells: Modulation by HMG CoA reductase inhibitors (statins). Mol Pathol 54:176-179
41. Hishikawa K, Oemar BS, Nakaki T 2001 Static pressure regulates connective tissue growth factor expression in human mesangial cells. J Biol Chem 276:16797-16803
42. Jedsadayanmata A, Chen CC, Kireeva ML, Lau LF, Lam SC 1999 Activation-dependent adhesion of human platelets to Cyr61 and Fisp12/mouse connective tissue growth factor is mediated through integrin α(IIb)β(3). J Biol Chem 274:24321-24327
43. Babic AM, Chen CC, Lau LF 1999 Fisp12/mouse connective tissue growth factor mediates endothelial cell adhesion and migration through integrin αv/β3, promotes endothelial cell survival, and induces angiogenesis in vivo. Mol Cell Biol 19:2958-2966
44. Chen C, Chen N, Lau L 2001 The angiogerdc factors Cyr61 and connective tissue growth factor induce adhesive signaling in primary human skin fibroblasts. J Biol Chem 276:10443-10452
45. Grotendorst GR, Okochi H, Hayashi N 1996 A novel transforming growth factor β response element controls the expression of the connective tissue growth factor gene. Cell Growth Differ 7:469-480
46. Yokoi H, Sugawara A, Mukoyama M, Mori K, Makino H, Suganami T, Nagae T, Yahata K, Fujinaga Y, Tanaka I, Nakao K 2001 Role of connective tissue growth factor in profibrotic action of transforming growth factor-β: A potential target for preventing renal fibrosis. Am J Kidney Dis 38:S134-S138
47. Grotendorst GR 1997 Connective tissue growth factor: A mediator of TGF-β action on fibroblasts. Cytokine Growth Factor Rev 8:171-179
48. Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M 1994 Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 91:11704-11708
49. Ziyadeh F, Hoffman B, Han D, Iglesias-De La Cruz M, Hong S, Isono M, Chen S, McGowan T, Sharma K 2000 Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-β antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97:8015-8020
50. Way KJ, King GL 2001 Increased cardiac expression of connective tissue growth factor by protein kinase C β2 and diabetes: Possible role in the development of myocardial fibrosis. Diabetes 50(Suppl 2):A30
51. Bach LA, Dean R, Youssef S, Cooper ME 2000 Aminoguanidine ameliorates changes in the IGF system in experimental diabetic nephropathy. Nephrol Dial Transplant 15:347-354
52. Wang SN, DeNichilo M, Brubaker C, Hirschberg R 2001 Connective tissue growth factor in tubulointerstitial injury of diabetic nephropathy. Kidney Int 60:96-105
53. Singh LP, Andy J, Anyamale V, Greene K, Alexander M, Crook ED 2001 Hexosamine-induced fibronectin protein synthesis in mesangial cells is associated with increases in cAMP responsive element binding (CREB) phosphorylation and nuclear CREB: The involvement of protein kinases A and C. Diabetes 50:2355-2362
54. Corbett JA, Tilton RG, Chang K, Hasan KS, Ido Y, Wang JL, Sweetland MA, Lancaster Jr JR, Williamson JR, McDaniel ML 1992 Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 41:552-556